Predictive Biomarkers Market Size & Growth Forecast 2027–2036, By Segments (Indication, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Predictive Biomarkers Market size was more than USD 32.3 billion in 2026 and is set to grow at a 18.72% CAGR between 2027 and 2036, attaining USD 179.66 billion by 2036. The industry revenue for 2027 is estimated at USD 37.53 billion.
Get more details on this report
Request Free Sample ReportPredictive Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 46.46% of the market, supported by advanced biomedical research, precision medicine infrastructure, sophisticated diagnostic laboratories, and increasing biomarker use in targeted treatment development.
- Asia Pacific is the fastest-growing region, driven by expanding healthcare infrastructure, biomedical research investment, molecular diagnostics access, and increasing adoption of personalized medicine and biomarker-based clinical trials.
Segment Momentum
- Cancer accounted for 40.17% of the market in 2026, driven by increasing use of biomarkers for treatment selection, therapeutic monitoring, and personalized oncology. Growing adoption of targeted therapies and immunotherapies strengthens demand for predictive testing.
- Diagnostics is the fastest-growing technology segment as healthcare providers increasingly use biomarkers to guide treatment decisions and patient stratification. Advances in molecular testing, next-generation sequencing, and liquid biopsies are expanding clinical testing capabilities and precision medicine adoption.
Market Expansion Drivers
- Expansion of precision medicine and oncology research.
- Integration of AI and multiomics in biomarker discovery.
- Government funding for predictive diagnostics.
Leading Market Participants
- Prominent companies in the predictive biomarkers market include Thermo Fisher Scientific (USA), Qiagen (Netherlands), Roche (Switzerland), Bio-Rad Laboratories (USA), Illumina (USA), Agilent Technologies (USA), Merck KGaA (Germany), Siemens Healthineers (Germany), Myriad Genetics (USA), Becton Dickinson (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 32.3 billion
- 2027 Estimated Market Size: USD 37.53 billion
- Projected Market Size: USD 179.66 billion by 2036
- Growth Forecast: 18.72% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Indication (Cancer) | Technology (Drug Discovery & Development)
- Emerging Opportunity Segment: Indication (Cancer) | Technology (Diagnostics)
Market Growth Drivers and Industry Trends
Expansion of precision medicine and oncology research
The expansion of precision medicine and oncology research is accelerating demand for predictive biomarkers as healthcare providers and researchers increasingly seek to identify patient subgroups that are more likely to respond to specific therapies. Biomarker-driven approaches support treatment selection, disease stratification, and monitoring of therapeutic response, while the growing complexity of targeted and immune-based treatments is increasing the need for reliable molecular indicators that can guide individualized clinical decisions.
Integration of AI and multiomics in biomarker discovery
The integration of artificial intelligence with multiomics approaches is transforming biomarker discovery by enabling researchers to analyze complex relationships across genomic, proteomic, transcriptomic, and other biological datasets. Advanced computational methods can identify subtle disease signatures and interactions that may be difficult to detect through conventional analysis, improving the ability to discover predictive markers associated with treatment response, disease progression, and patient-specific outcomes.
Government funding for predictive diagnostics
Government funding for predictive diagnostics is supporting market growth by encouraging research programs focused on early disease identification, personalized treatment strategies, and improved clinical decision-making. Public investment in biomedical research, translational medicine, and diagnostic infrastructure is helping advance biomarker validation and clinical adoption while creating an ecosystem that supports the development of more predictive and patient-specific diagnostic approaches.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expansion of precision medicine and oncology research | 6% | Short term (≤ 2 yrs) | North America; Europe; spillover Asia Pacific | Medium | Fast |
| Integration of AI and multiomics in biomarker discovery | 7% | Medium term (2–5 yrs) | North America; Europe; spillover Asia Pacific | Low | Moderate |
| Government funding for predictive diagnostics | 5.7% | Long term (5+ yrs) | North America; Europe; spillover Asia Pacific | High | Slow |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America dominated the predictive biomarkers market, accounting for 46.46% share. The region’s leading position is supported by advanced biomedical research capabilities, established precision medicine infrastructure, and the growing integration of biomarker-based approaches into clinical research and disease management. Healthcare providers and researchers are increasingly emphasizing the identification of biological indicators that can help predict disease progression, assess treatment response, and support the selection of appropriate therapeutic interventions. The expansion of personalized medicine and targeted treatment development is strengthening demand for predictive biomarkers across oncology, neurological disorders, cardiovascular conditions, and other complex diseases. In addition, the presence of sophisticated diagnostic laboratories, established clinical research networks, and advanced molecular testing capabilities supports the development and evaluation of biomarker-based applications. Growing interest in identifying patients most likely to benefit from specific therapies is also encouraging pharmaceutical research programs to incorporate predictive biomarkers into clinical development and treatment evaluation. Continued progress in genomic analysis, molecular diagnostics, and data-driven healthcare research is reinforcing the region’s position in the market.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to witness the fastest growth in the predictive biomarkers market, supported by expanding healthcare infrastructure, increasing investment in biomedical research, and the gradual adoption of precision medicine across the region. Growing awareness of personalized treatment approaches is encouraging healthcare institutions and research organizations to explore biomarkers that can support earlier disease assessment, treatment selection, and monitoring of therapeutic outcomes. The rising burden of chronic diseases and cancer is further increasing the need for diagnostic approaches that provide more individualized clinical insights. Improvements in laboratory infrastructure, wider access to molecular diagnostic technologies, and the expansion of clinical research activities are creating favorable conditions for market development. Additionally, growing collaboration among healthcare providers, research institutions, and pharmaceutical developers is supporting the investigation of predictive biomarkers for drug discovery and clinical trials. As healthcare systems increasingly emphasize targeted therapies and evidence-based treatment decisions, the adoption of biomarker-driven approaches is expected to expand across clinical research and routine healthcare applications.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Translational Biomarker CommercializationThe U.S. predictive biomarkers market prioritizes translating biomarker discoveries into clinically validated tools for patient selection, treatment response, and disease-risk assessment. Pharmaceutical companies and diagnostic developers are emphasizing companion diagnostics, multi-omics approaches, and clinical trial integration to improve precision medicine development and strengthen biomarker-based therapeutic strategies.
Germany 🇩🇪
Precision Diagnostics IntegrationGermany is focused on integrating predictive biomarkers into precision diagnostics, oncology, and clinical research workflows. Priorities include robust analytical validation, standardized testing, and collaboration between pharmaceutical companies, diagnostic laboratories, and healthcare institutions to support clinically actionable biomarker applications and improve treatment-selection processes.
Japan 🇯🇵
Personalized Medicine BiomarkersJapan's predictive biomarkers market emphasizes biomarker-driven personalization of therapies, particularly across oncology and age-related diseases. Market priorities include clinically reliable diagnostic platforms, genomic and molecular profiling, and partnerships connecting pharmaceutical research with healthcare providers to identify patients most likely to benefit from targeted treatments.
South Korea 🇰🇷
Genomic Biomarker InnovationSouth Korea is advancing predictive biomarker applications through genomics, molecular diagnostics, and precision oncology. Commercial priorities include developing validated biomarker assays, expanding clinical use of sequencing-based diagnostics, and strengthening links between biotechnology companies, hospitals, and pharmaceutical developers to support targeted therapy selection and clinical development.
France 🇫🇷
Clinical Biomarker TranslationFrance's predictive biomarkers market centers on translating molecular discoveries into clinically useful tools for precision medicine and therapeutic development. Priorities include oncology biomarker testing, genomic profiling, clinical validation, and collaboration across research institutions, diagnostic providers, and pharmaceutical companies to integrate predictive biomarkers into treatment pathways and trials.
Italy 🇮🇹
Biomarker Clinical AdoptionItaly's predictive biomarkers market is focused on expanding clinically validated applications, particularly in oncology and personalized treatment strategies. Market priorities include improving access to molecular testing, strengthening laboratory capabilities, and connecting biomarker research with pharmaceutical trials and hospital-based care to support more informed patient-selection and treatment decisions.
Predictive Biomarkers Market Share (%), by Indication, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportIndication Segment Analysis: Cancer (Largest & Fastest-Growing Segment)
The cancer indication segment dominated the predictive biomarkers market, accounting for a 40.17% share in 2026, driven by the increasing use of biomarker-based approaches in cancer diagnosis, treatment selection, and therapeutic monitoring. Predictive biomarkers play a critical role in identifying patients who are more likely to respond to specific cancer therapies, enabling healthcare providers to develop personalized treatment strategies and improve clinical decision-making. The growing prevalence of cancer and increasing adoption of precision oncology are encouraging pharmaceutical companies and healthcare institutions to integrate biomarker testing into clinical research and treatment pathways. Furthermore, the expanding development of targeted therapies and immunotherapies is creating demand for reliable biomarkers that can predict treatment response and identify potential resistance mechanisms. The cancer segment is also expected to witness the fastest growth in market share as advancements in molecular profiling, genomic sequencing, and companion diagnostics improve the identification and clinical validation of cancer-related biomarkers. Increasing investments in oncology research and the growing emphasis on personalized medicine are further accelerating the adoption and share of predictive biomarkers across cancer care through 2026.
Technology Segment Analysis: Drug Discovery & Development (Largest Segment) vs Diagnostics (Fastest-Growing Segment)
The drug discovery and development segment accounted for the largest technology market share of 34.13% in 2026, supported by the growing integration of biomarker technologies throughout pharmaceutical research and clinical development processes. Predictive biomarkers enable researchers to identify suitable patient populations, evaluate therapeutic responses, and assess the effectiveness of drug candidates during clinical trials. Their application helps pharmaceutical companies improve clinical trial design, reduce development uncertainties, and identify potential treatment-related adverse reactions. The increasing focus on precision medicine is further encouraging the use of predictive biomarkers in developing targeted therapies for complex diseases, particularly cancer and other chronic conditions. Additionally, advancements in genomics, proteomics, and molecular diagnostics are strengthening biomarker discovery capabilities, allowing researchers to identify biological characteristics associated with treatment outcomes. The growing emphasis on personalized drug development and more efficient clinical research is reinforcing the central market share held by predictive biomarkers within pharmaceutical development activities.
The diagnostics segment is projected to register the fastest growth in market share within the technology segment as healthcare providers increasingly adopt biomarker-based testing to support personalized diagnosis and treatment decisions through 2026. Predictive diagnostic technologies help identify molecular and genetic characteristics that indicate how patients may respond to specific therapies, enabling more targeted clinical interventions. The growing demand for early disease identification, treatment stratification, and continuous monitoring is encouraging the integration of advanced biomarker testing into routine healthcare practices. Furthermore, improvements in molecular testing platforms, next-generation sequencing, and liquid biopsy technologies are expanding the ability to detect clinically relevant biomarkers with greater precision. The increasing availability of companion diagnostics and the growing adoption of precision medicine are also supporting the expansion of this predictive biomarkers market segment, helping diagnostic tools capture a larger overall share.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Indication | Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Others | Cancer | Cancer |
| Technology | Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, Others | Drug Discovery & Development | Diagnostics |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Multi-omics integration is driving predictive biomarker development toward holistic biological profiling, yet capturing multi-layered molecular data introduces complex normalization and platform compatibility challenges. Consequently, competitive differentiation centers on generating reproducible biological insights that offer superior predictive power compared to existing individual markers. Parallel progress in high-throughput companion diagnostics addresses scale, though commercial viability hinges on balancing turnaround times, diagnostic accuracy, and cost within existing decision pathways. Underpinning these technological strides is the imperative for rigorous clinical validation across broad patient demographics, as poor reproducibility risks regulatory and clinical rejection. Ultimately, bioinformatics platforms act as the critical bridge, translating complex datasets into actionable clinical strategies, where transparent, reliable interpretation outweighs raw algorithm sophistication.
Top players in the predictive biomarkers market:
- Thermo Fisher Scientific (USA)
- Qiagen (Netherlands)
- Roche (Switzerland)
- Bio-Rad Laboratories (USA)
- Illumina (USA)
- Agilent Technologies (USA)
- Merck KGaA (Germany)
- Siemens Healthineers (Germany)
- Myriad Genetics (USA)
- Becton Dickinson (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific (USA) | |||||||
| Qiagen (Netherlands) | |||||||
| Roche (Switzerland) | |||||||
| Bio-Rad Laboratories (USA) | |||||||
| Illumina (USA) | |||||||
| Agilent Technologies (USA) | |||||||
| Merck KGaA (Germany) | |||||||
| Siemens Healthineers (Germany) | |||||||
| Myriad Genetics (USA) | |||||||
| Becton Dickinson (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Leica Biosystems | June 2026 | Leica Biosystems expanded its commercial partnership with Versant Diagnostics to facilitate the initial deployment of the Aperio GT Elite digital pathology system at PRW Laboratories. This implementation strengthens the company's operational footprint in advancing digital workflows for predictive biomarker analysis. |
| Novigenix SA | March 2026 | Novigenix SA completed the formation of Novigenix AI as an independent spin-out entity specializing in artificial intelligence-driven immune intelligence. The new organization builds upon the parent company's immunotranscriptomic diagnostics capabilities to address emerging applications in precision biomarker development. |
| Kneu Health | October 2025 | Kneu Health secured a $5.6 million oversubscribed seed financing round co-led by Oxford Science Enterprises and Cedars-Sinai. The capital infusion is intended to accelerate the U.S. market expansion of the company's precision neurology platform dedicated to predictive biomarker applications in Parkinson's disease and dementia. |
| Lunit | September 2024 | Lunit entered into a strategic collaboration with Roche to integrate its SCOPE PD-L1 22C3 TPS artificial intelligence technology into the navify Digital Pathology platform. This deployment expands the commercial reach of AI-driven tools designed to enhance cancer biomarker testing within routine clinical workflows. |
| Illumina, Inc. | August 2024 | Illumina, Inc. received FDA approval for its in vitro diagnostic TruSight Oncology Comprehensive test alongside two companion diagnostic indications. The regulatory clearance strengthens the company's commercial position by enabling precise genomic profiling to support predictive biomarker identification in oncology. |
| Proscia | July 2024 | Proscia formed a strategic partnership with Nucleai to expand the availability of artificial intelligence-enabled predictive biomarkers. The initiative combines Proscia's pathology solutions with Nucleai's spatial AI biomarker technology to map cellular interactions and enhance the prediction of therapeutic outcomes. |
| Volastra Therapeutics | March 2024 | Volastra Therapeutics established strategic partnerships with Microsoft, Function Oncology, and Tailor Bio to advance its therapeutics pipeline. These collaborations leverage advanced computational and biological platforms to identify and validate predictive biomarkers across various tumor types. |
| OncoHost | November 2023 | OncoHost successfully developed a proteomics-based predictive biomarker designed to identify immune-related adverse events in non-small cell lung cancer patients. The innovation supports clinical decision-making by personalizing treatment regimens and mitigating risks associated with immune checkpoint inhibitors. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Predictive Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Biomarker Type | Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Epigenetic Biomarkers, Imaging Biomarkers |
| Validation Stage | Discovery & Research, Analytical Validation, Clinical Validation, Clinical Utility & Adoption |
| Companion Diagnostic Integration | Standalone Predictive Biomarkers, Biomarkers Integrated with Companion Diagnostics, Biomarkers Embedded in Multi-Parameter Diagnostic Panels |
Predictive Biomarkers Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Biomarker Commercialization Pathways |
|
| Clinical Trial Enrichment Strategies |
|
| Biomarker Data & Evidence Strategy |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How much revenue does the predictive biomarkers market generate?
How is the predictive biomarkers industry projected to perform over the next decade?
How is the expansion of precision medicine increasing demand for predictive biomarkers?
How are AI and multiomics approaches transforming predictive biomarker discovery?
Why does cancer dominate the predictive biomarkers market?
How is diagnostics becoming a faster-growing technology segment in the predictive biomarkers market?
Why does North America lead the predictive biomarkers market?
What is driving predictive biomarkers market growth in Asia Pacific?
Who are the leading players in the predictive biomarkers landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook